Skip to main content
. 2020 Mar 4;9(3):610. doi: 10.3390/cells9030610

Figure 4.

Figure 4

Applying monobody advantages to the antibody scaffold. Monobodies are fused with antibody fragments to extend half-life and generate bivalency. Replacing either (A) Antigen-binding fragments or (B) individual variable domains. (C) mAbtyrins extend this combination through developing by specifics by fusing monobodies to 1 of 4 positions on the C- or N-terminal ends of either chain.